Free tool
FAERS Monitor: Selarsdi
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761343 or its brand name (Selarsdi, Ustekinumab-Aekn). Reports on generic versions are filed under their own applications.
Reports
6
Serious
3
50% of reports
Hospitalization
2
Death reported
1
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- vomiting2
- abdominal discomfort1
- abdominal pain upper1
- alopecia1
- anti-cyclic citrullinated peptide antibody positive1
- arthralgia1
- arthropathy1
- asthenia1
- blood cholesterol increased1
- brain fog1
- bursitis1
- c-reactive protein increased1
- cerebral venous sinus thrombosis1
- confusional state1
- decreased appetite1
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2025 | 3 |
| 2026 | 3 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,153 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| cerebral venous sinus thrombosis | 1 | 4157.6 | 693.8 | 1,037 |
| anti-cyclic citrullinated peptide antibody positive | 1 | 489.3 | 81.8 | 121 |
| bursitis | 1 | 288.9 | 48.3 | 71 |
| brain fog | 1 | 223.7 | 37.4 | 55 |
| c-reactive protein increased | 1 | 96.3 | 16.1 | 23 |
| blood cholesterol increased | 1 | 75.2 | 12.6 | 18 |
| arthropathy | 1 | 63.1 | 10.5 | 15 |
| confusional state | 1 | 21.7 | 3.6 | 5 |
| abdominal discomfort | 1 | 20.9 | 3.5 | 4 |
| alopecia | 1 | 17.9 | 3.0 | 4 |
| abdominal pain upper | 1 | 17.0 | 2.8 | 3 |
| decreased appetite | 1 | 15.1 | 2.5 | 3 |
| vomiting | 2 | 14.9 | 4.8 | 14 |
| asthenia | 1 | 9.3 | 1.6 | 1 |
| arthralgia | 1 | 8.4 | 1.4 | 1 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.